Innovative Diagnostic Platform MiRNA Scientific's proprietary miR Disease Management Platform offers a non-invasive urine test for prostate cancer, highlighting an opportunity to target urological and other cancer types with similar liquid biopsy solutions.

Growing Market Presence With revenue ranging between 10 million and 25 million and a specialized focus on molecular cancer diagnostics, the company presents potential for expansion into broader oncology markets and early detection segments.

Strategic Partnerships Leveraging cloud-based technologies like Cloudflare and Insightly CRM, MiRNA Scientific is positioned to build collaborations with healthcare providers, laboratories, and biotech firms to accelerate adoption of its platform.

Size and Agility As a smaller entity with 11-50 employees, there are opportunities for rapid sales engagement, personalized customer service, and tailored solutions in niche cancer diagnostics markets.

Competitive Edge Unique non-invasive testing technology provides a competitive advantage over traditional biopsy methods, making it appealing for healthcare institutions focused on improving patient outcomes and reducing invasive procedures.